(NYSE: JNJ) JOHNSON & JOHNSON's forecast annual revenue growth rate of 3.26% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.17%.
JOHNSON & JOHNSON's revenue in 2022 is $94,880,000,000.On average, 5 Wall Street analysts forecast JNJ's revenue for 2022 to be $254,253,536,534,818, with the lowest JNJ revenue forecast at $250,738,383,697,748, and the highest JNJ revenue forecast at $262,911,248,443,052. On average, 5 Wall Street analysts forecast JNJ's revenue for 2023 to be $265,002,528,712,763, with the lowest JNJ revenue forecast at $262,748,101,531,204, and the highest JNJ revenue forecast at $269,839,729,392,984.
In 2024, JNJ is forecast to generate $274,568,190,025,057 in revenue, with the lowest revenue forecast at $270,031,321,758,333 and the highest revenue forecast at $276,889,254,825,900.